101 related articles for article (PubMed ID: 33032941)
21. Immune checkpoint inhibitors for head and neck squamous cell carcinoma: Current landscape and future directions.
Kao HF; Lou PJ
Head Neck; 2019 Oct; 41 Suppl 1():4-18. PubMed ID: 31573752
[TBL] [Abstract][Full Text] [Related]
22. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.
Chow LQM; Haddad R; Gupta S; Mahipal A; Mehra R; Tahara M; Berger R; Eder JP; Burtness B; Lee SH; Keam B; Kang H; Muro K; Weiss J; Geva R; Lin CC; Chung HC; Meister A; Dolled-Filhart M; Pathiraja K; Cheng JD; Seiwert TY
J Clin Oncol; 2016 Nov; 34(32):3838-3845. PubMed ID: 27646946
[TBL] [Abstract][Full Text] [Related]
23. Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040).
Pai SI; Faivre S; Licitra L; Machiels JP; Vermorken JB; Bruzzi P; Gruenwald V; Giglio RE; Leemans CR; Seiwert TY; Soulieres D
J Immunother Cancer; 2019 Apr; 7(1):96. PubMed ID: 30944020
[TBL] [Abstract][Full Text] [Related]
24. Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial.
Elbers JBW; Al-Mamgani A; Tesseslaar MET; van den Brekel MWM; Lange CAH; van der Wal JE; Verheij M; Zuur CL; de Boer JP
Radiother Oncol; 2020 Jan; 142():79-84. PubMed ID: 31563412
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapeutic Approaches to the Management of Head and Neck Cancer.
Nan X; Gold KA; Cohen E
Oncology (Williston Park); 2018 Dec; 32(12):617-9, 625-6. PubMed ID: 30632130
[TBL] [Abstract][Full Text] [Related]
26. Gene status of head and neck squamous cell carcinoma cell lines and cetuximab-mediated biological activities.
Kondo N; Tsukuda M; Taguchi T; Nakazaki K; Sakakibara A; Takahashi H; Toth G; Nishimura G
Cancer Sci; 2011 Sep; 102(9):1717-23. PubMed ID: 21631644
[TBL] [Abstract][Full Text] [Related]
27. Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC).
Walsh L; Gillham C; Dunne M; Fraser I; Hollywood D; Armstrong J; Thirion P
Radiother Oncol; 2011 Jan; 98(1):38-41. PubMed ID: 21159400
[TBL] [Abstract][Full Text] [Related]
28. [Cetuximab in head and neck squamous cell carcinoma: a systematic review and Meta-analysis].
Song Q; Li X; Li B
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jan; 29(1):67-75. PubMed ID: 25966559
[TBL] [Abstract][Full Text] [Related]
29. 18F-FLT PET changes during radiotherapy combined with cetuximab in head and neck squamous cell carcinoma patients.
Hoeben BA; Troost EG; Bussink J; van Herpen CM; Oyen WJ; Kaanders JH
Nuklearmedizin; 2014; 53(2):60-6. PubMed ID: 24468965
[TBL] [Abstract][Full Text] [Related]
30. Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: A randomised phase II study.
Forster MD; Dillon MT; Kocsis J; Remenár É; Pajkos G; Rolland F; Greenberg J; Harrington KJ
Eur J Cancer; 2019 Dec; 123():36-47. PubMed ID: 31648099
[TBL] [Abstract][Full Text] [Related]
31. Tumour response and safety of cetuximab in a window pre-operative study in patients with squamous cell carcinoma of the head and neck.
Schmitz S; Hamoir M; Reychler H; Magremanne M; Weynand B; Lhommel R; Hanin FX; Duprez T; Michoux N; Rommel D; Lonneux M; Cappoen N; Gillain A; Machiels JP
Ann Oncol; 2013 Sep; 24(9):2261-6. PubMed ID: 23704200
[TBL] [Abstract][Full Text] [Related]
32. How Standard Is Second-Line Cetuximab in Recurrent or Metastatic Head and Neck Cancer in 2017?
Szturz P; Seiwert TY; Vermorken JB
J Clin Oncol; 2017 Jul; 35(20):2229-2231. PubMed ID: 28471725
[No Abstract] [Full Text] [Related]
33. FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy.
Larkins E; Blumenthal GM; Yuan W; He K; Sridhara R; Subramaniam S; Zhao H; Liu C; Yu J; Goldberg KB; McKee AE; Keegan P; Pazdur R
Oncologist; 2017 Jul; 22(7):873-878. PubMed ID: 28533473
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck.
Saada-Bouzid E; Peyrade F; Guigay J
Curr Opin Oncol; 2019 May; 31(3):146-151. PubMed ID: 30893146
[TBL] [Abstract][Full Text] [Related]
35. RAS/PI3K crosstalk and cetuximab resistance in head and neck squamous cell carcinoma.
Rampias T; Giagini A; Siolos S; Matsuzaki H; Sasaki C; Scorilas A; Psyrri A
Clin Cancer Res; 2014 Jun; 20(11):2933-46. PubMed ID: 24696319
[TBL] [Abstract][Full Text] [Related]
36. Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment-induced reduction in EGFR, pEGFR, and pSrc.
Jedlinski A; Garvin S; Johansson AC; Edqvist PH; Ponten F; Roberg K
J Oral Pathol Med; 2017 Oct; 46(9):717-724. PubMed ID: 28036101
[TBL] [Abstract][Full Text] [Related]
37. Treatment patterns and outcomes among patients with recurrent/metastatic squamous cell carcinoma of the head and neck.
Nadler E; Joo S; Boyd M; Black-Shinn J; Chirovsky D
Future Oncol; 2019 Mar; 15(7):739-751. PubMed ID: 30511880
[TBL] [Abstract][Full Text] [Related]
38. Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population.
Fernández-Mateos J; Seijas-Tamayo R; Mesía R; Taberna M; Pastor Borgoñón M; Pérez-Ruiz E; Adansa Klain JC; Vázquez Fernández S; Del Barco Morillo E; Lozano A; González Sarmiento R; Cruz-Hernández JJ;
Oral Oncol; 2016 Dec; 63():38-43. PubMed ID: 27938998
[TBL] [Abstract][Full Text] [Related]
39. Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposals for a revised grading system and consensus management guidelines.
Bernier J; Russi EG; Homey B; Merlano MC; Mesía R; Peyrade F; Budach W
Ann Oncol; 2011 Oct; 22(10):2191-200. PubMed ID: 21606209
[TBL] [Abstract][Full Text] [Related]
40. Controversies and role of HPV16 in recurrent/metastatic squamous cell cancers of the head and neck.
Misiukiewicz K; Bonomi M; Demicco E; Posner M
Ann Oncol; 2014 Aug; 25(8):1667-8. PubMed ID: 24875798
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
